title: [Arterial hypertension and cardiovascular risk: need for a combined strategy of intervention].
abstract: Arterial hypertension represents one of the most common conditions associated with an increased cardiovascular risk. New evidences support the need to adopt a global approach to the treatment of cardiovascular risk in hypertensive subjects by using drugs with proven benefits, not only for blood pressure control, but also for their pleiotropic effects. A greater understanding of the pathogenetic mechanisms of hypertension would provide a better strategy for preventing and treating this condition. Angiotensin II seems to be responsible for triggering vascular inflammation by inducing oxidative stress, resulting in up-regulation of pro-inflammatory mediators that lead to endothelial dysfunction and vascular injury. The interaction of angiotensin II, oxidative stress and endothelial dysfunction might be a target of a new integrated approach with important clinical implications.
authors.affiliation: Dipartimento di Clinica e Terapia Medica, Università di Roma "La Sapienza", Roma.
authors.forename: V
authors.initials: V
authors.lastname: Paoletti
authors.forename: V
authors.initials: V
authors.lastname: Raparelli
authors.forename: P
authors.initials: P
authors.lastname: Ferroni
authors.forename: A
authors.initials: A
authors.lastname: Scarno
authors.forename: F
authors.initials: F
authors.lastname: Trinchieri
authors.forename: S
authors.initials: S
authors.lastname: Basili
authors.forename: G
authors.initials: G
authors.lastname: Davì
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D024821:Metabolic Syndrome / Q000188:drug therapy; D017202:Myocardial Ischemia / Q000453:epidemiology / Q000517:prevention & control; D018384:Oxidative Stress; D012306:Risk
chemical_list: D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D000804:Angiotensin II